The Asia Pacific Inhaled Nitric Oxide Market would witness market growth of 8.9% CAGR during the forecast period (2020-2026). Inhaled Nitric Oxide is basically a vasodilator that makes precisely selective pulmonary vasodilation. Large number of lab and clinical research studies have been conducted to describe the physiology, biochemistry, side effects, and clinical efficacy of inhaled nitric oxide in many diseases of children and adults.
The usage of inhaled nitric oxide is widely adopted across the world. Inhaled nitric oxide is majorly utilized to cure pulmonary hypertension and hypoxemia in a large number of adults and infants across the world. There are many cases in which inhaled nitric oxide has proved to be the lifesaver of the patient. However, there are many experimental usages of the inhaled nitric oxide which uses a distinct approach to add value benefits to inhaled nitric oxide. Many organizations have conducted studies to find out the ways to cure diseases with the acute rejection of the transplanted lung and sickle cell crisis.
The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the inhaled nitric oxide market during the forecast period.
Based on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Repellent Market by Country in 2019, growing at a CAGR of 7.2 % during the forecast period. The India market is experiencing a CAGR of 10.5% during (2020 - 2026). Additionally, The Japan market is anticipated to grow at a CAGR of 10.6% during (2020 - 2026).
Free Valuable Insights: Inhaled Nitric Oxide Market in Asia Pacific is expected to register a CAGR of 8.9% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 